AUSTIN, TX, September 6, 2011 – Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™. “We are establishing the Oncoprex brand in the oncology sector in recognition of our advancing development programs. We anticipate that when approved, Oncoprex will […]